Randomized Controlled Trial of the Topical JAK Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia

October 2025 in “ Journal of Investigative Dermatology ”

Aubrey Martin, Neda Shokrian, Kristen J. Kelley, Joel Corrêa da Rosa, Ester Del-Duca, Robert Bissonnette, Ole E. Sørensen, Anders Bacher Nielsen, Emma Guttman‐Yassky, Maryanne M. Senna

delgocitinib frontal fibrosing alopecia Jak inhibitor CXCL9 T helper 1 transcriptomic profile

TLDR Delgocitinib cream may help treat frontal fibrosing alopecia.

This study investigated the effects of delgocitinib cream on frontal fibrosing alopecia (FFA) in a randomized, double-blind trial involving 30 adult females. Over 12 weeks, the cream significantly downregulated the T helper 1-related biomarker CXCL9 and showed a small but significant improvement in the transcriptomic profile of lesions compared to the cream vehicle. Delgocitinib was well-tolerated and associated with improvements in clinical severity endpoints, suggesting potential as a topical treatment for FFA. However, the study's limitations include its small sample size and exploratory nature.

View this study on jidonline.org →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

research A Phase 2a Trial of Brepocitinib for Cicatricial Alopecia

17 citations , October 2024 in “Journal of the American Academy of Dermatology”

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

research Enhanced Insights Into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies

1 citations , May 2024 in “Dermatology and Therapy”

Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.

research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia

3 citations , February 2024 in “Journal of the American Academy of Dermatology”

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

research Janus Kinase Inhibition for the Treatment of Refractory Frontal Fibrosing Alopecia: A Case Series and Review of the Literature

16 citations , August 2023 in “JAAD Case Reports”

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review

2 citations , June 2023 in “Indian journal of dermatology, venereology, and leprology”

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

research Frontal Fibrosing Alopecia Shows Robust T Helper 1 and Janus Kinase 3 Skewing

34 citations , June 2020 in “British journal of dermatology/British journal of dermatology, Supplement”

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.